Please wait
0001716166
EX-FILING FEES
0001716166
2026-02-13
2026-02-13
0001716166
1
2026-02-13
2026-02-13
0001716166
2
2026-02-13
2026-02-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Exhibit
107
Calculation
of Filing Fee Table
S-3
(Form
Type)
Vivos
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered Securities
| | |
Security Type | |
Security Class Title | |
Fee Calculation Rule | | |
Amount Registered(1) | | |
Proposed Maximum Offering Price Per Unit | | |
Maximum Aggregate Offering Price | | |
Fee Rate | | |
Amount of Registration Fee | |
| Fees to Be Paid | |
Equity | |
Common Stock issuable upon exercise of Series A Warrant | |
| 457 | (g) | |
| 1,982,356 | | |
$ | 2.09 | (2) | |
$ | 4,143,124 | | |
| 0.00013810 | | |
$ | 572.17 | |
| Fees to Be Paid | |
Equity | |
Common Stock issuable upon exercise of Series B Warrant | |
| 457 | (g) | |
| 1,982,356 | | |
$ | 2.09 | (2) | |
$ | 4,143,124 | | |
| 0.00013810 | | |
$ | 572.17 | |
| | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
Total Offering Amounts | | |
| | | |
| | | |
$ | 8,286,248 | | |
| | | |
$ | 1,144.34 | |
| | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
Total Fees Previously Paid | | |
| | | |
| | | |
| — | | |
| — | | |
| — | |
| | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
Total Fee Offsets | | |
| | | |
| | | |
| — | | |
| — | | |
| — | |
| | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
Net Fee Due | | |
| | | |
| | | |
| | | |
| | | |
$ | 1,144.34 | |
| (1) |
Pursuant
to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also
cover any additional shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), in
connection with any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration
that increases the number of outstanding shares of Common Stock. |
| (2) |
Estimated
solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(g) of the Securities Act. The proposed
maximum offering price per share are calculated based on the exercise price of the subject warrants. |
N/A